Should You Buy Alibaba Stock Despite the Risks?
Markets rebounded slightly after U.S. President Donald Trump announced a…
Sell
30
YMAB Quote, Financials, Valuation and Earnings
Last price:
$4.14
Seasonality move
:
11.61%
Day range:
$4.11 - $4.40
52-week range:
$3.84 - $17.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.08x
P/B ratio:
2.02x
Volume:
181.5K
Avg. volume:
297.5K
1-year change:
-73.14%
Market cap:
$186.3M
Revenue:
$87.7M
EPS (TTM):
-$0.67
Analysts' Opinion
-
Consensus RatingY-mAbs Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $16.10, Y-mAbs Therapeutics has an estimated upside of 290.78% from its current price of $4.12.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 27.18% downside risk from its current price of $4.12.
Fair Value
-
According to the consensus of 8 analysts, Y-mAbs Therapeutics has 290.78% upside to fair value with a price target of $16.10 per share.
YMAB vs. S&P 500
-
Over the past 5 trading days, Y-mAbs Therapeutics has underperformed the S&P 500 by -24.33% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Y-mAbs Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Y-mAbs Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Y-mAbs Therapeutics reported revenues of $26.5M.
Earnings Growth
-
Y-mAbs Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Y-mAbs Therapeutics reported earnings per share of -$0.15.
Enterprise value:
119.1M
EV / Invested capital:
--
Price / LTM sales:
2.08x
EV / EBIT:
--
EV / Revenue:
1.36x
PEG ratio (5yr expected):
-0.17x
EV / Free cash flow:
-7.58x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$72.4M
Return On Assets:
-23.32%
Net Income Margin (TTM):
-33.83%
Return On Equity:
-30.91%
Return On Invested Capital:
-30.91%
Operating Margin:
-22.4%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $65.3M | $84.8M | $87.7M | $23.4M | $26.5M | |
| Gross Profit | $57.7M | $73.4M | $72.4M | $21.3M | $18.7M | |
| Operating Income | -$94.8M | -$25.7M | -$31.2M | -$3.2M | -$5.9M | |
| EBITDA | -$94M | -$24.9M | -$30.7M | -$3M | -$5.8M | |
| Diluted EPS | -$2.18 | -$0.49 | -$0.67 | -$0.02 | -$0.15 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $122.4M | $202.3M | $130.4M | $111.1M | $98.5M | |
| Total Assets | $132M | $212.8M | $141.5M | $127.9M | $119.9M | |
| Current Liabilities | $19.5M | $27.9M | $28.3M | $20.1M | $23.7M | |
| Total Liabilities | $26.2M | $32.7M | $32.2M | $26.9M | $27.9M | |
| Total Equity | $105.8M | $180.1M | $109.2M | $101M | $92M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$75.9M | -$27.2M | -$15.7M | -$8M | -$1.9M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $84K | $100K | $4.3M | $100K | $986K | |
| Free Cash Flow | -$75.9M | -$27.2M | -$15.7M | -$8M | -$1.9M | |
YMAB
Sector
Market Cap
$186.3M
$35.8M
Price % of 52-Week High
23.18%
43.18%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.79%
1-Year Price Total Return
-73.14%
-40.56%
Beta (5-Year)
0.711
0.742
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.69
200-day SMA
Sell
Level
$9.88
Bollinger Bands (100)
Sell
Level
4.55 - 8.71
Chaikin Money Flow
Buy
Level
3.7M
20-day SMA
Sell
Level
$4.61
Relative Strength Index (RSI14)
Sell
Level
40.56
ADX Line
Sell
Level
18.31
Williams %R
Buy
Level
-82.5
50-day SMA
Sell
Level
$5.08
MACD (12, 26)
Sell
Level
-0.17
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
17.4M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.5089)
Buy
CA Score
(Annual)
Level (-0.0422)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.3861)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Stock Forecast FAQ
In the current month, YMAB has received 7 Buy ratings 0 Hold ratings, and 1 Sell ratings. The YMAB average analyst price target in the past 3 months is $16.10.
-
Where Will Y-mAbs Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Y-mAbs Therapeutics share price will rise to $16.10 per share over the next 12 months.
-
What Do Analysts Say About Y-mAbs Therapeutics?
Analysts are divided on their view about Y-mAbs Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Y-mAbs Therapeutics is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Y-mAbs Therapeutics's Price Target?
The price target for Y-mAbs Therapeutics over the next 1-year time period is forecast to be $16.10 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is YMAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Y-mAbs Therapeutics is a Buy. 7 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of YMAB?
You can purchase shares of Y-mAbs Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Y-mAbs Therapeutics shares.
-
What Is The Y-mAbs Therapeutics Share Price Today?
Y-mAbs Therapeutics was last trading at $4.14 per share. This represents the most recent stock quote for Y-mAbs Therapeutics. Yesterday, Y-mAbs Therapeutics closed at $4.12 per share.
-
How To Buy Y-mAbs Therapeutics Stock Online?
In order to purchase Y-mAbs Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Intel Struggling Against AMD?
Due to its disappointing reports, so-so management, and lack of…
Will PayPal Stock Recover or Keep Sliding?
Payments platform behemoth PayPal Holdings, Inc. (NASDAQ:PYPL) is going through…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
49
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Buy
71
PEGA alert for Apr 24
Pegasystems [PEGA] is up 3.13% over the past day.
Buy
67
SMMT alert for Apr 24
Summit Therapeutics [SMMT] is up 10.38% over the past day.
Sell
36
ENPH alert for Apr 24
Enphase Energy [ENPH] is up 1.44% over the past day.
